(Alexandria, VA, Friday, June 4, 2021) – Cancer experts from around the world will gather to explore the latest research impacting patient care across the entire cancer care continuum, from prevention and screening to symptom management and survivorship, at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO).

The 2021 ASCO Annual Meeting, taking place online June 4-8, will bring together one of the largest, most diverse audiences in oncology and provide engaging broadcast and on-demand presentations of the latest cutting-edge research. The theme of this year’s meeting is, “Equity: Every Patient. Every Day. Everywhere.” Discussions during the meeting will help identify ways to ensure that all patients have access to and benefit from the latest cancer advances and high-quality cancer care.

Highlights include:

• Phase 3 data on novel uses of immunotherapy – First data on adjuvant immunotherapy in early-stage lung cancer; studies on toripalimab in the frontline setting in advanced head and neck cancer, pembrolizumab post-nephrectomy in the frontline setting for patients with renal cell carcinoma, and nivolumab, either in a dual immunotherapy regimen, or with chemotherapy in advanced esophageal cancer;
• PARP inhibitor in BRCA and HER2 negative breast cancers – Phase 3 data from a first-in-class study in the adjuvant setting;
• Medicaid & cancer survival – Large-scale study examining impact of states’ Medicaid income limits on long-term survival;
• Increased PSA screening in younger African American men – Large study examining the association between screening intensity with prostate cancer severity at diagnosis and mortality;
• Novel radiation-based therapy for metastatic prostate cancer – Phase 3 data on treatment utilizing a molecule that attaches itself to cancer cells’ PSMA receptors;
• Adjuvant chemotherapy following chemoradiation for cervical cancer – Long-awaited results from an international phase 3 trial in locally-advanced disease; and
• Incidence and trends of HPV-related cancers in the United States– Population-based study to assess the impact of screening and recommendations on HPV-related cancers.

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net.